

**Supplementary Table 2.** Baseline characteristics by age

|   | 12-21                |                    |                       | 22-35                |                   |                       |
|---|----------------------|--------------------|-----------------------|----------------------|-------------------|-----------------------|
|   | Treatment<br>(n= 26) | Placebo<br>(n= 12) | Total 12-21<br>(n=38) | Treatment<br>(n= 12) | Placebo<br>(n= 8) | Total 22-35<br>(n=20) |
| <b>Age in years</b>                               | 15.6 (2.72)          | 15.3 (2.23)        | 15.5 (2.54)           | 27.7 (4.48)          | 28.1 (3.87)       | 27.9 (4.15)           |
| <b>Men</b>  | 18 (69.2%)           | 6 (50.0%)          | 24 (63.2%)            | 6 (50.0)             | 5 (62.5)          | 11 (55.0)             |
| <b>Ethnic origin</b>                              |                      |                    |                       |                      |                   |                       |
| <b>White</b>                                      | 21 (80.8%)           | 9 (75.0%)          | 30 (78.9%)            | 11 (91.7%)           | 8                 | 19 (95.0%)            |
| <b>Non-white</b>                                  | 5 (19.2%)            | 3 (25.0%)          | 8 (21.1%)             | 1 (8.3%)             | 0                 | 1 (5.0%)              |
| <b>Body-mass index</b>                            | 22.489 (3.3942)      | 23.241 (2.4466)    | 22.726 (3.1128)       | 23.603 (3.2800)      | 26.047 (3.9608)   | 24.581 (3.6765)       |
| <b>Days since diagnosis</b>                       | 67.9 (21.31)         | 83.0 (17.33)       | 72.7 (21.14)          | 71.3 (20.97)         | 66.8 (15.22)      | 69.5 (18.58)          |
| <b>Baseline 2-hour C-peptide AUC (pmol/ml)</b>    | 0.97 (0.390)         | 0.98 (0.565)       | 0.97 (0.445)          | 0.62 (0.161)         | 0.86 (0.415)      | 0.71 (0.306)          |
| <b>Baseline Peak C-peptide (pmol/ml)</b>          | 1.24 (0.461)         | 1.22 (0.620)       | 1.23 (0.508)          | 0.91 (0.204)         | 1.13 (0.441)      | 1.00 (0.330)          |
| <b>Baseline HbA1c (%)</b>                         | 6.81 (0.966)         | 6.73 (1.405)       | 6.78 (1.104)          | 6.62 (1.804)         | 6.88 (0.997)      | 6.72 (1.506)          |
| <b>Baseline insulin use (U/kg per day)</b>        | 0.37 (0.246)         | 0.47 (0.273)       | 0.41 (0.256)          | 0.26 (0.099)         | 0.33 (0.157)      | 0.29 (0.127)          |
| <b>Days of insulin use prior to randomization</b> | 68.8 (19.2)          | 83 (17.3)          | 73.3 (19.6)           | 71.3 (20.9)          | 66.8 (15.2)       | 69.5 (18.5)           |
| <b>GAD65 (% positive)</b>                         | 84.62%               | 91.67%             | 86.84%                | 75%                  | 85.71%            | 78.95%                |
| <b>IA.2ic (% positive)</b>                        | 65.38%               | 50%                | 60.53%                | 58.33%               | 57.14%            | 57.89%                |
| <b>ZnT8 (% positive)</b>                          | 64%                  | 50%                | 59.46%                | 66.67%               | 42.86%            | 57.89%                |
| <b>ICA (% positive)</b>                           | 61.90%               | 33.33%             | 51.52%                | 70%                  | 100%              | 80%                   |